CA Patent

CA2928042C — Inhibitors of the fibroblast growth factor receptor

Assigned to Blueprint Medicines Corp · Expires 2022-05-10 · 4y expired

What this patent protects

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

USPTO Abstract

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

Drugs covered by this patent

Patent Metadata

Patent number
CA2928042C
Jurisdiction
CA
Classification
—
Expires
2022-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Blueprint Medicines Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.